Anti-Laminin4 antibodies specific for LG4-5
US10059761B2 · kind B2 · utility
7Cited by
6References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 12, 2015 |
| Grant date | Aug 28, 2018 |
| Priority date | — |
| Expiry date | Apr 1, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/78
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin α4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.